Centogene: Kim Stratton, Andreas Busch

Centogene has nominated Kim Stratton as its permanent CEO. She had taken over as interim CEO from Andrin Oswald in December, who had stepped down to take a medical leave of absence. Stratton was most recently CEO of Orphazyme. Before that, she was head of international commercial for the specialty and rare disease portfolio of Shire Pharmaceuticals, and prior to that, she held various senior management roles at Novartis.

In addition, Centogene has nominated Andreas Busch to its supervisory board. Since 2019, he has been chief innovation officer and CSO at Cyclerion Therapeutics. Prior to that, he was head of R&D and CSO at Shire, and before that, he held various senior leadership positions at Bayer, including head of drug discovery and member of the executive committee for the pharmaceuticals division. Busch holds a PhD in pharmacology from Goethe University Frankfurt in Germany.